Search

Your search keyword '"Ponziani FR (ORCID:0000-0002-5924-6238)"' showing total 12 results
Start Over Author "Ponziani FR (ORCID:0000-0002-5924-6238)"
12 results on '"Ponziani FR (ORCID:0000-0002-5924-6238)"'

1. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Author

Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), Rossi, M (ORCID:0000-0002-4539-5670), Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), and Rossi, M (ORCID:0000-0002-4539-5670)

Abstract

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

Published
2023

2. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis

Author

Rinninella, Emanuele, Cintoni, Marco, Raoul, P, Ponziani, Francesca Romana, Pompili, Maurizio, Pozzo, Carmelo, Strippoli, Antonia, Bria, Emilio, Tortora, Giampaolo, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E (ORCID:0000-0002-9165-2367), Cintoni M (ORCID:0000-0002-9610-0748), Ponziani FR (ORCID:0000-0002-5924-6238), Pompili M (ORCID:0000-0001-6699-7980), Pozzo C, Strippoli A, Bria E (ORCID:0000-0002-2333-704X), Tortora G (ORCID:0000-0002-1378-4962), Gasbarrini A (ORCID:0000-0002-7278-4823), Mele MC. (ORCID:0000-0003-0153-5819), Rinninella, Emanuele, Cintoni, Marco, Raoul, P, Ponziani, Francesca Romana, Pompili, Maurizio, Pozzo, Carmelo, Strippoli, Antonia, Bria, Emilio, Tortora, Giampaolo, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E (ORCID:0000-0002-9165-2367), Cintoni M (ORCID:0000-0002-9610-0748), Ponziani FR (ORCID:0000-0002-5924-6238), Pompili M (ORCID:0000-0001-6699-7980), Pozzo C, Strippoli A, Bria E (ORCID:0000-0002-2333-704X), Tortora G (ORCID:0000-0002-1378-4962), Gasbarrini A (ORCID:0000-0002-7278-4823), and Mele MC. (ORCID:0000-0003-0153-5819)

Abstract

Low muscle mass has been associated with worse clinical outcomes in various cancers. This work investigated whether, during tyrosine kinases inhibitors (TKIs) therapy, low muscle mass was associated with treatment toxicity and survival outcomes. A systematic literature search was performed in Pubmed, Web of Science, and Scopus databases from inception to June 2020, based on fixed inclusion and exclusion criteria. Effect sizes were estimated with hazard ratios (HR) and odds ratios (OR) with 95% confidence interval (CI) and heterogeneity was assessed by measuring inconsistency (I2) based on the Chi squared test. A total of 24 retrospective studies were identified, enrolling patients treated with sorafenib (n = 12), sunitinib (n = 6), lenvatinib (n = 3), regorafenib (n = 2), gefitinib (n = 1), imatinib (n = 1), and pazopanib (n = 1). Thirteen studies were deemed eligible for pooled analyses. Meta-analyses found a significant effect of low muscle mass on dose-limiting toxicity (DLT) (OR 2.40, 95% CI 1.26-4.58, p = 0.008, I2 = 51%) in patients treated with TKI therapy. A subgroup analysis by treatment showed an association between DLT and low muscle during sorafenib or sunitinib, although not significant. A significant association between low skeletal muscle index and poorer overall survival was observed in HCC patients treated with sorafenib (HR 1.45, 95% CI 1.07-1.96, p = 0.02). For other TKIs, although some results showed an association between low muscle mass and worse outcomes, the number of studies for each TKI therapy was too small to reach conclusions. Skeletal muscle mass could influence the prognosis of some TKI-treated patients. This effect is demonstrated in sorafenib-treated HCC patients but remains almost unexplored in other cancer patients undergoing TKI therapy. Further prospective studies with large sample size and sufficient follow-up are needed to clarify the role of muscle mass in the metabolism of TKI-based cancer treatment, and its association with

Published
2020

3. Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges.

Author

Rinninella, Emanuele, Cintoni, M, Raoul, P, Pozzo, Carmelo, Strippoli, Antonia, Ponziani, Francesca Romana, Pompili, Maurizio, Bria, Emilio, Tortora, Giampaolo, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E (ORCID:0000-0002-9165-2367), Pozzo C, Strippoli A, Ponziani FR (ORCID:0000-0002-5924-6238), Pompili M (ORCID:0000-0001-6699-7980), Bria E (ORCID:0000-0002-2333-704X), Tortora G (ORCID:0000-0002-1378-4962), Gasbarrini A (ORCID:0000-0002-7278-4823), Mele MC. (ORCID:0000-0003-0153-5819), Rinninella, Emanuele, Cintoni, M, Raoul, P, Pozzo, Carmelo, Strippoli, Antonia, Ponziani, Francesca Romana, Pompili, Maurizio, Bria, Emilio, Tortora, Giampaolo, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E (ORCID:0000-0002-9165-2367), Pozzo C, Strippoli A, Ponziani FR (ORCID:0000-0002-5924-6238), Pompili M (ORCID:0000-0001-6699-7980), Bria E (ORCID:0000-0002-2333-704X), Tortora G (ORCID:0000-0002-1378-4962), Gasbarrini A (ORCID:0000-0002-7278-4823), and Mele MC. (ORCID:0000-0003-0153-5819)

Abstract

In cancer patients, loss of muscle mass is significantly associated with low tolerability of chemotherapy and poor survival. Despite the great strides in the treatment of cancer, targeted therapies such as tyrosine kinase inhibitors (TKIs) could exacerbate muscle wasting. Over recent years, the impact of skeletal muscle loss during TKI therapy on clinical outcomes has been in the spotlight. In this review, we focus on the different molecular pathways of TKIs potentially involved in muscle wasting. Then, we report the results of the studies assessing the effects of different TKI therapies-such as sorafenib, regorafenib, sunitinib, and lenvatinib-on muscle mass, and highlight their potential clinical implications. Finally, we discuss an integrative nutritional approach to be adopted during TKI treatment. The assessment of muscle mass from computerized tomography imaging could be helpful in predicting toxicity and prognosis in patients treated with TKI such as sorafenib. Early recognition of low muscle mass and effective personalized nutritional support could prevent or attenuate muscle mass wasting. However, the role of nutrition is still overlooked, and future clinical trials are needed to find the optimal nutritional support to countermeasure muscle mass depletion during TKI therapy.

Published
2020

4. HEPATOCATT STUDY GROUP. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.

Author

De Gaetano, Am, Catalano, M, Pompili, Maurizio, Marini, Mg, Rodríguez Carnero, P, Gullì, C, Infante, A, Iezzi, Roberto, Ponziani, Francesca Romana, Cerrito, Lucia, Marrone, Giuseppe, Giuliante, Felice, Ardito, Francesco, Rapaccini, Gl, Vecchio, Fm, Giraldi, Luca, Manfredi, Riccardo, Pompili M (ORCID:0000-0001-6699-7980), Iezzi R (ORCID:0000-0002-2791-481X), Ponziani FR (ORCID:0000-0002-5924-6238), Cerrito L, Marrone G, Giuliante F (ORCID:0000-0001-9517-8220), Ardito F (ORCID:0000-0003-1596-2862), Giraldi L, Manfredi R (ORCID:0000-0002-4972-9500), De Gaetano, Am, Catalano, M, Pompili, Maurizio, Marini, Mg, Rodríguez Carnero, P, Gullì, C, Infante, A, Iezzi, Roberto, Ponziani, Francesca Romana, Cerrito, Lucia, Marrone, Giuseppe, Giuliante, Felice, Ardito, Francesco, Rapaccini, Gl, Vecchio, Fm, Giraldi, Luca, Manfredi, Riccardo, Pompili M (ORCID:0000-0001-6699-7980), Iezzi R (ORCID:0000-0002-2791-481X), Ponziani FR (ORCID:0000-0002-5924-6238), Cerrito L, Marrone G, Giuliante F (ORCID:0000-0001-9517-8220), Ardito F (ORCID:0000-0003-1596-2862), Giraldi L, and Manfredi R (ORCID:0000-0002-4972-9500)

Abstract

OBJECTIVE: To evaluate the performance of major features, ancillary features, and categories of Liver Imaging Reporting and Data System (LI-RADS) version 2018 at magnetic resonance (MR) imaging in the differentiation of small hepatocellular carcinoma (HCC) from dysplastic nodules (DNs). PATIENTS AND METHODS: This retrospective study included cirrhotic patients with pathologically proven untreated HCCs and DNs (≤ 2 cm) and liver MR imaging performed with gadobenate dimeglumine contrast agent within 3 months before pathological analysis, between 2015 and 2018. 37 patients with 43 observations (17 HCCs and 26 DNs) met the inclusion criteria. Two radiologists assessed major and ancillary imaging features for each liver observation and assigned a LI-RADS v2018 category in consensus. Estimates of diagnostic performance of major features, ancillary features, and LI-RADS categories were assessed based on their sensitivity, specificity, positive (PPV), and negative predictive values (NPV). RESULTS: Major features (nonrim arterial phase hyperenhancement, nonperipheral "washout", and enhancing "capsule") had a sensitivity of 94.1%, 88.2%, and 41.2%, and a specificity of 57.7%, 42.3%, and 88.5% for HCC, respectively. Ancillary features (hepatobiliary phase hypointensity, mild-moderate T2 hyperintensity, restricted diffusion, and fat in the lesion more than adjacent liver) had a sensitivity of 94.1%, 64.7%, 58.8%, and 11.8%, and a specificity of 26.9%, 61.5%, 65.4%, and 76.9% for HCC, respectively. The LR-5 category (determined by using major features only vs. the combination of major and ancillary features) had a sensitivity of 88.2% at both evaluations and a specificity of 76.9% and 80.8% for HCC, respectively. The combination of LR-4, LR-5 categories (determined by using major features only vs. the combination of major and ancillary features) had a sensitivity of 94.1% at both interpretations and a specificity of 65.4% and 26.9% for HCC, respectively. The use of ancillary fea

Published
2019

5. HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?

Author

Iezzi, R, Pompili, M, Posa, A, Carchesio, F, Siciliano, M, Annicchiarico, Be, Agnes, S, Giuliante, F, Garcovich, M, Cerrito, L, Ponziani, Fr, Basso, M, Cassano, A, Rapaccini, Gl, De Gaetano, Anna Maria, Gasbarrini, A, Manfredi, R, Iezzi R (ORCID:0000-0002-2791-481X), Pompili M (ORCID:0000-0001-6699-7980), Siciliano M, Agnes S (ORCID:0000-0002-3341-4221), Giuliante F (ORCID:0000-0001-9517-8220), Garcovich M (ORCID:0000-0001-8967-6688), Cerrito L, Ponziani FR (ORCID:0000-0002-5924-6238), Basso M, Cassano A (ORCID:0000-0002-3311-7163), De Gaetano AM (ORCID:0000-0002-7493-9462), Gasbarrini A (ORCID:0000-0002-7278-4823), Manfredi R (ORCID:0000-0002-4972-9500), Iezzi, R, Pompili, M, Posa, A, Carchesio, F, Siciliano, M, Annicchiarico, Be, Agnes, S, Giuliante, F, Garcovich, M, Cerrito, L, Ponziani, Fr, Basso, M, Cassano, A, Rapaccini, Gl, De Gaetano, Anna Maria, Gasbarrini, A, Manfredi, R, Iezzi R (ORCID:0000-0002-2791-481X), Pompili M (ORCID:0000-0001-6699-7980), Siciliano M, Agnes S (ORCID:0000-0002-3341-4221), Giuliante F (ORCID:0000-0001-9517-8220), Garcovich M (ORCID:0000-0001-8967-6688), Cerrito L, Ponziani FR (ORCID:0000-0002-5924-6238), Basso M, Cassano A (ORCID:0000-0002-3311-7163), De Gaetano AM (ORCID:0000-0002-7493-9462), Gasbarrini A (ORCID:0000-0002-7278-4823), and Manfredi R (ORCID:0000-0002-4972-9500)

Abstract

PURPOSE: This study was designed to assess the feasibility and safety of a single-step combined therapy using radiofrequency ablation and transarterial chemoembolization (RFA + TACE) in patients with hepatocellular carcinoma (HCC) and uncontrolled coagulopathy. The study also aimed to compare the effectiveness of this approach with TACE alone, performed in a control group. MATERIAL AND METHODS: One hundred and forty-three consecutive cirrhotic patients having a single HCC < 8 cm were enrolled in this observational prospective single-center study from January 2010 to June 2017 and were divided, according to coagulation tests, into three groups (A: low risk; B: intermediate risk and C: high risk of bleeding). The feasibility and safety of a single-step combined treatment (RFA followed by TACE) were evaluated in terms of technical success rate, periprocedural complications, and laboratory values variations. Tumor response obtained at 1-month CT follow-up for group C was compared with that of control group, composed by 16 matched patients with severe coagulopathy and single HCC < 8 cm, who underwent only TACE in a previous period, performed by the same operator. RESULTS: Technical success was achieved in all patients, without any major complications. Minor complications rate was significantly higher in group C after RFA; however, the patients were successfully treated with subsequent TACE therapy, without any differences between pre- and post-procedural laboratory values. One-month complete response rates were similar in all the three groups; however, the response rates of group C were significantly higher as compared to that of the control TACE Group (p < .001). CONCLUSION: The single-step RFA plus TACE therapy allows expansion of the indication for percutaneous thermal ablation, allowing to also include cases previously contraindicated due to the procedural high-risk of complications associated with bleeding, thus improving short-term patient outcome.

Published
2019

6. Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible?

Author

Iezzi, Roberto, Pompili, Maurizio, Posa, A, Cachesio, F, Siciliano, Massimo, Annicchiarico, Brigida Eleonora, Agnes, Salvatore, Giuliante, Felice, Garcovich, M, Cerrito, L, Ponziani, Francesca Romana, Basso, Michele, Cassano, Alessandra, Rapaccini, Gian Ludovico, De Gaetano, Anna Maria, Gasbarrini, Antonio, Manfredi, Riccardo, Iezzi R (ORCID:0000-0002-2791-481X), Pompili M (ORCID:0000-0001-6699-7980), Siciliano M, Annicchiarico B, Agnes S (ORCID:0000-0002-3341-4221), Giuliante F (ORCID:0000-0001-9517-8220), ponziani fr (ORCID:0000-0002-5924-6238), Basso M, Cassano A (ORCID:0000-0002-3311-7163), Rapaccini G (ORCID:0000-0002-6467-857X), De Gaetano AM (ORCID:0000-0002-7493-9462), Gasbarrini A (ORCID:0000-0002-7278-4823), Manfredi R (ORCID:0000-0002-4972-9500), Iezzi, Roberto, Pompili, Maurizio, Posa, A, Cachesio, F, Siciliano, Massimo, Annicchiarico, Brigida Eleonora, Agnes, Salvatore, Giuliante, Felice, Garcovich, M, Cerrito, L, Ponziani, Francesca Romana, Basso, Michele, Cassano, Alessandra, Rapaccini, Gian Ludovico, De Gaetano, Anna Maria, Gasbarrini, Antonio, Manfredi, Riccardo, Iezzi R (ORCID:0000-0002-2791-481X), Pompili M (ORCID:0000-0001-6699-7980), Siciliano M, Annicchiarico B, Agnes S (ORCID:0000-0002-3341-4221), Giuliante F (ORCID:0000-0001-9517-8220), ponziani fr (ORCID:0000-0002-5924-6238), Basso M, Cassano A (ORCID:0000-0002-3311-7163), Rapaccini G (ORCID:0000-0002-6467-857X), De Gaetano AM (ORCID:0000-0002-7493-9462), Gasbarrini A (ORCID:0000-0002-7278-4823), and Manfredi R (ORCID:0000-0002-4972-9500)

Published
2019

7. The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology

Author

Duarte, Sm, Stefano, Jt, Miele, Luca, Ponziani, Francesca Romana, Souza, M, Rodrigues, L, Costa, Fg, Toda, K, Mazo, Df, Sabino, Ec, Carrilho, Fj, Gasbarrini, Antonio, Oliveira, Cp, Miele, L (ORCID:0000-0003-3464-0068), Ponziani, FR (ORCID:0000-0002-5924-6238), Gasbarrini, A (ORCID:0000-0002-7278-4823), Duarte, Sm, Stefano, Jt, Miele, Luca, Ponziani, Francesca Romana, Souza, M, Rodrigues, L, Costa, Fg, Toda, K, Mazo, Df, Sabino, Ec, Carrilho, Fj, Gasbarrini, Antonio, Oliveira, Cp, Miele, L (ORCID:0000-0003-3464-0068), Ponziani, FR (ORCID:0000-0002-5924-6238), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

n/a

Published
2017

8. Treatment of Portal Vein Tumor Thrombosis (PVTT) Can Impact Survival of Patients With Advanced HCC?

Author

Cesario, V, Rinninella, E, Ponziani, Fr, Garcovich, M, Roccarina, D, Campanale, M, Di Rienzo, Ta, Barbaro, F, Siciliano, M, Annicchiarico, Be, Pompili, M, Rapaccini, Gl, Riccardi, L, Grieco, A, Miele, L, Iezzi, R, De Gaetano, Am, Di Stasio, E, Gasbarrini, Gb, Bonomo, L, Zocco, Ma, Gasbarrini, A, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Rapaccini, GL (ORCID:0000-0002-6467-857X), Miele, L (ORCID:0000-0003-3464-0068), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Di Stasio, E (ORCID:0000-0003-1047-4261), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), Zocco, MA (ORCID:0000-0002-0814-9542), Gasbarrini, A (ORCID:0000-0002-7278-4823), Cesario, V, Rinninella, E, Ponziani, Fr, Garcovich, M, Roccarina, D, Campanale, M, Di Rienzo, Ta, Barbaro, F, Siciliano, M, Annicchiarico, Be, Pompili, M, Rapaccini, Gl, Riccardi, L, Grieco, A, Miele, L, Iezzi, R, De Gaetano, Am, Di Stasio, E, Gasbarrini, Gb, Bonomo, L, Zocco, Ma, Gasbarrini, A, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Rapaccini, GL (ORCID:0000-0002-6467-857X), Miele, L (ORCID:0000-0003-3464-0068), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Di Stasio, E (ORCID:0000-0003-1047-4261), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), Zocco, MA (ORCID:0000-0002-0814-9542), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2013

9. Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience

Author

Rinninella, Emanuele, Ponziani, Francesca Romana, Biolato, Marco, Siciliano, M, D'Aversa, F, Laterza, L, Ianiro, Gianluca, Montagna, M, Tortora, Annalisa, Cesario, Valentina, Campanale, Mariachiara, De Matthaeis, Nicoletta, Miele, Luca, Riccardi, Laura, Zocco, Maria Assunta, Saviano, Angela, Abbate, Valeria, Avolio, Alfonso Wolfango, Vellone, Maria, Basso, M, Iezzi, Roberto, De Gaetano, Anna Maria, Bonomo, Lorenzo, Agnes, Salvatore, Giuliante, Felice, Vecchio, Fabio Maria, Barone, C, Rapaccini, Gian Ludovico, Pompili, Maurizio, Grieco, A, Gasbarrini, Antonio, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Biolato, M, Ianiro, G (ORCID:0000-0002-8318-0515), Tortora, A, Cesario, V, Campanale, M, de Matthaeis, N, Miele, L (ORCID:0000-0003-3464-0068), Riccardi, L, Zocco, MA (ORCID:0000-0002-0814-9542), Saviano, A (ORCID:0000-0002-2820-7180), Abbate, V, Avolio, AW (ORCID:0000-0003-2491-7625), Vellone, M (ORCID:0000-0002-7628-4092), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Bonomo, L (ORCID:0000-0001-5101-9367), Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Vecchio, FM (ORCID:0000-0002-9197-2264), Rapaccini, GL (ORCID:0000-0002-6467-857X), Pompili, M (ORCID:0000-0001-6699-7980), Gasbarrini, A (ORCID:0000-0002-7278-4823), Rinninella, Emanuele, Ponziani, Francesca Romana, Biolato, Marco, Siciliano, M, D'Aversa, F, Laterza, L, Ianiro, Gianluca, Montagna, M, Tortora, Annalisa, Cesario, Valentina, Campanale, Mariachiara, De Matthaeis, Nicoletta, Miele, Luca, Riccardi, Laura, Zocco, Maria Assunta, Saviano, Angela, Abbate, Valeria, Avolio, Alfonso Wolfango, Vellone, Maria, Basso, M, Iezzi, Roberto, De Gaetano, Anna Maria, Bonomo, Lorenzo, Agnes, Salvatore, Giuliante, Felice, Vecchio, Fabio Maria, Barone, C, Rapaccini, Gian Ludovico, Pompili, Maurizio, Grieco, A, Gasbarrini, Antonio, Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Biolato, M, Ianiro, G (ORCID:0000-0002-8318-0515), Tortora, A, Cesario, V, Campanale, M, de Matthaeis, N, Miele, L (ORCID:0000-0003-3464-0068), Riccardi, L, Zocco, MA (ORCID:0000-0002-0814-9542), Saviano, A (ORCID:0000-0002-2820-7180), Abbate, V, Avolio, AW (ORCID:0000-0003-2491-7625), Vellone, M (ORCID:0000-0002-7628-4092), Iezzi, R (ORCID:0000-0002-2791-481X), De Gaetano, AM (ORCID:0000-0002-7493-9462), Bonomo, L (ORCID:0000-0001-5101-9367), Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Vecchio, FM (ORCID:0000-0002-9197-2264), Rapaccini, GL (ORCID:0000-0002-6467-857X), Pompili, M (ORCID:0000-0001-6699-7980), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2013

10. New Therapeutic Perspectives for Management of Advanced Hepatocellular Carcinoma With Hepatic Arteriovenous Fistula: Balloon-Occluded Percutaneous Radio-Frequency Thermal Ablation (RFA) Plus Transcatheter Arterial Chemoembolization (TACE)

Author

Iezzi, R, Cesario, V, Campanale, M, Pecere, S, Barbaro, F, Rinninella, E, Ponziani, Fr, La Torre, M, Annicchiarico, Be, Siciliano, M, Pompili, M, Grieco, A, Miele, L, Rapaccini, Gl, Riccardi, L, Zocco, Ma, Milani, A, De Gaetano, Am, Gasbarrini, Gb, Bonomo, L, Gasbarrini, A, Iezzi, R (ORCID:0000-0002-2791-481X), Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Miele, L (ORCID:0000-0003-3464-0068), Rapaccini, GL (ORCID:0000-0002-6467-857X), Zocco, MA (ORCID:0000-0002-0814-9542), Milani, A (ORCID:0000-0003-1303-7737), De Gaetano, AM (ORCID:0000-0002-7493-9462), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), Gasbarrini, A (ORCID:0000-0002-7278-4823), Iezzi, R, Cesario, V, Campanale, M, Pecere, S, Barbaro, F, Rinninella, E, Ponziani, Fr, La Torre, M, Annicchiarico, Be, Siciliano, M, Pompili, M, Grieco, A, Miele, L, Rapaccini, Gl, Riccardi, L, Zocco, Ma, Milani, A, De Gaetano, Am, Gasbarrini, Gb, Bonomo, L, Gasbarrini, A, Iezzi, R (ORCID:0000-0002-2791-481X), Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Miele, L (ORCID:0000-0003-3464-0068), Rapaccini, GL (ORCID:0000-0002-6467-857X), Zocco, MA (ORCID:0000-0002-0814-9542), Milani, A (ORCID:0000-0003-1303-7737), De Gaetano, AM (ORCID:0000-0002-7493-9462), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2012

11. Single-Step Balloon-Occluded Percutaneous Radio-Frequency Thermal Ablation (RFA) Plus Transcatheter Arterial Chemoembolization (TACE) for Treatment of 'Complex' Unresectable Hepatocellular Carcinoma

Author

Iezzi, R, Cesario, V, Campanale, M, Di Rienzo, Ta, Gigante, G, Caracciolo, G, Rinninella, E, Ponziani, Fr, La Torre, M, Annicchiarico, Be, Siciliano, M, Pompili, M, Grieco, A, Miele, L, Rapaccini, Gl, Riccardi, L, Zocco, Ma, Milani, A, Santoro, M, De Gaetano, Am, Gasbarrini, Gb, Bonomo, L, Gasbarrini, A, Iezzi, R (ORCID:0000-0002-2791-481X), Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Miele, L (ORCID:0000-0003-3464-0068), Rapaccini, GL (ORCID:0000-0002-6467-857X), Zocco, MA (ORCID:0000-0002-0814-9542), Milani, A (ORCID:0000-0003-1303-7737), De Gaetano, AM (ORCID:0000-0002-7493-9462), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), Gasbarrini, A (ORCID:0000-0002-7278-4823), Iezzi, R, Cesario, V, Campanale, M, Di Rienzo, Ta, Gigante, G, Caracciolo, G, Rinninella, E, Ponziani, Fr, La Torre, M, Annicchiarico, Be, Siciliano, M, Pompili, M, Grieco, A, Miele, L, Rapaccini, Gl, Riccardi, L, Zocco, Ma, Milani, A, Santoro, M, De Gaetano, Am, Gasbarrini, Gb, Bonomo, L, Gasbarrini, A, Iezzi, R (ORCID:0000-0002-2791-481X), Rinninella, E (ORCID:0000-0002-9165-2367), Ponziani, FR (ORCID:0000-0002-5924-6238), Annicchiarico, BE, Pompili, M (ORCID:0000-0001-6699-7980), Miele, L (ORCID:0000-0003-3464-0068), Rapaccini, GL (ORCID:0000-0002-6467-857X), Zocco, MA (ORCID:0000-0002-0814-9542), Milani, A (ORCID:0000-0003-1303-7737), De Gaetano, AM (ORCID:0000-0002-7493-9462), Gasbarrini, GB, Bonomo, L (ORCID:0000-0001-5101-9367), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2012

12. HCC PERSONALIZED TREATMENT IN THE MULTIMODAL MANAGEMENT ERA: THE HEPATOCAT GROUP EXPERIENCE

Author

Ponziani, Francesca Romana, Zocco, Maria Assunta, De Gaetano, Anna Maria, Novi, M, Siciliano, M, Milani, Alessandro, Annicchiarico, Eb, Miele, Luca, Rinninella, Emanuele, Tortora, Annalisa, Ainora, Maria Elena, Gasbarrini, Giovanni Battista, Agnes, Salvatore, Bombardieri, G, Giuliante, Felice, Grieco, A, Nuzzo, Gennaro, Pompili, Maurizio, Rapaccini, Gian Ludovico, Di Stasio, Enrico, Gasbarrini, Antonio, Ponziani, FR (ORCID:0000-0002-5924-6238), Zocco, MA (ORCID:0000-0002-0814-9542), De Gaetano, AM (ORCID:0000-0002-7493-9462), Milani, A (ORCID:0000-0003-1303-7737), Miele, L (ORCID:0000-0003-3464-0068), Rinninella, E (ORCID:0000-0002-9165-2367), Tortora, A, Ainora, ME, Gasbarrini, G, Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Nuzzo, G, Pompili, M (ORCID:0000-0001-6699-7980), Rapaccini, GL (ORCID:0000-0002-6467-857X), Di Stasio, E (ORCID:0000-0003-1047-4261), Gasbarrini, A (ORCID:0000-0002-7278-4823), Ponziani, Francesca Romana, Zocco, Maria Assunta, De Gaetano, Anna Maria, Novi, M, Siciliano, M, Milani, Alessandro, Annicchiarico, Eb, Miele, Luca, Rinninella, Emanuele, Tortora, Annalisa, Ainora, Maria Elena, Gasbarrini, Giovanni Battista, Agnes, Salvatore, Bombardieri, G, Giuliante, Felice, Grieco, A, Nuzzo, Gennaro, Pompili, Maurizio, Rapaccini, Gian Ludovico, Di Stasio, Enrico, Gasbarrini, Antonio, Ponziani, FR (ORCID:0000-0002-5924-6238), Zocco, MA (ORCID:0000-0002-0814-9542), De Gaetano, AM (ORCID:0000-0002-7493-9462), Milani, A (ORCID:0000-0003-1303-7737), Miele, L (ORCID:0000-0003-3464-0068), Rinninella, E (ORCID:0000-0002-9165-2367), Tortora, A, Ainora, ME, Gasbarrini, G, Agnes, S (ORCID:0000-0002-3341-4221), Giuliante, F (ORCID:0000-0001-9517-8220), Nuzzo, G, Pompili, M (ORCID:0000-0001-6699-7980), Rapaccini, GL (ORCID:0000-0002-6467-857X), Di Stasio, E (ORCID:0000-0003-1047-4261), and Gasbarrini, A (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results